Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.

The Scottish Medicines Consortium (SMC) said it could not accept Kymriah (tisagenlecleucel) for adult patients with diffuse B cell lymphoma who have relapsed or not responded after two previous lines of treatment.

Despite being considered under the PACE process, the committee did not recommend tisagenlecleucel “because of uncertainties in the company’s evidence around its long term benefits”.

Read the full article by Selina McKee here.